{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:13:18Z","timestamp":1788865998846,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76572-7","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:17:42Z","timestamp":1786364262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression in mice"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2416-7724","authenticated-orcid":false,"given":"Juliana","family":"Hofst\u00e4tter Azambuja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saigopalakrishna S.","family":"Yerneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Crentsil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela N.","family":"Debom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Klei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6935-2855","authenticated-orcid":false,"given":"Mei","family":"Smyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaim T.","family":"Sneiderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina E.","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-1977","authenticated-orcid":false,"given":"Rajesh","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aivi T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie L.","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2034-2684","authenticated-orcid":false,"suffix":"IV","given":"John W.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Meridew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9509-5417","authenticated-orcid":false,"given":"Yijen Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna","family":"Ekambaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3537-8605","authenticated-orcid":false,"given":"Dong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete J.","family":"Gough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8074-2287","authenticated-orcid":false,"given":"Ari","family":"Melnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3953-8022","authenticated-orcid":false,"given":"Gary","family":"Kohanbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6105-1704","authenticated-orcid":false,"given":"Riyue","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4880-7172","authenticated-orcid":false,"given":"Peter C.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9875-5043","authenticated-orcid":false,"given":"Linda M.","family":"McAllister-Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"76572_CR1","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","volume":"18","author":"PD Delgado-Lopez","year":"2016","unstructured":"Delgado-Lopez, P. D. & Corrales-Garcia, E. M. Survival in glioblastoma: a review on the impact of treatment modalities. Clin. Transl. Oncol. 18, 1062\u20131071 (2016).","journal-title":"Clin. Transl. Oncol."},{"key":"76572_CR2","first-page":"744","volume":"27","author":"FS Cantidio","year":"2022","unstructured":"Cantidio, F. S., Gil, G. O. B., Queiroz, I. N. & Regalin, M. Glioblastoma - treatment and obstacles. Rep. Pr. Oncol. Radiother. 27, 744\u2013753 (2022).","journal-title":"Rep. Pr. Oncol. Radiother."},{"key":"76572_CR3","doi-asserted-by":"crossref","unstructured":"Angom, R. S., Nakka, N. M. R. & Bhattacharya, S. Advances in glioblastoma therapy: an update on current approaches. Brain Sci. 13, 1536 (2023).","DOI":"10.3390\/brainsci13111536"},{"key":"76572_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/13543784.2023.2267982","volume":"32","author":"TA Nelson","year":"2023","unstructured":"Nelson, T. A. & Dietrich, J. Investigational treatment strategies in glioblastoma: progress made and barriers to success. Expert Opin. Investig. Drugs 32, 921\u2013930 (2023).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"76572_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin, H. et al. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J. Hematol. Oncol. 17, 31 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"76572_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3389\/fphar.2019.00506","volume":"10","author":"I Prionisti","year":"2019","unstructured":"Prionisti, I., Buhler, L. H., Walker, P. R. & Jolivet, R. B. Harnessing microglia and macrophages for the treatment of glioblastoma. Front. Pharm. 10, 506 (2019).","journal-title":"Front. Pharm."},{"key":"76572_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8903482","volume":"2022","author":"SA Richard","year":"2022","unstructured":"Richard, S. A. The pivotal immunoregulatory functions of microglia and macrophages in glioma pathogenesis and therapy. J. Oncol. 2022, 8903482 (2022).","journal-title":"J. Oncol."},{"key":"76572_CR8","doi-asserted-by":"publisher","first-page":"104158","DOI":"10.1016\/j.cellimm.2020.104158","volume":"355","author":"J Cheng","year":"2020","unstructured":"Cheng, J., Maurer, L. M., Kang, H., Lucas, P. C. & McAllister-Lucas, L. M. Critical protein-protein interactions within the CARMA1-BCL10-MALT1 complex: take-home points for the cell biologist. Cell Immunol. 355, 104158 (2020).","journal-title":"Cell Immunol."},{"key":"76572_CR9","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1515\/hsz-2016-0216","volume":"397","author":"I Meininger","year":"2016","unstructured":"Meininger, I. & Krappmann, D. Lymphocyte signaling and activation by the CARMA1-BCL10-MALT1 signalosome. Biol. Chem. 397, 1315\u20131333 (2016).","journal-title":"Biol. Chem."},{"key":"76572_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/MOH.0000000000000257","volume":"23","author":"M Juilland","year":"2016","unstructured":"Juilland, M. & Thome, M. Role of the CARMA1\/BCL10\/MALT1 complex in lymphoid malignancies. Curr. Opin. Hematol. 23, 402\u2013409 (2016).","journal-title":"Curr. Opin. Hematol."},{"key":"76572_CR11","doi-asserted-by":"publisher","first-page":"102568","DOI":"10.1016\/j.ctrv.2023.102568","volume":"117","author":"TJ O\u2019Neill","year":"2023","unstructured":"O\u2019Neill, T. J., Tofaute, M. J. & Krappmann, D. Function and targeting of MALT1 paracaspase in cancer. Cancer Treat. Rev. 117, 102568 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"76572_CR12","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019102030","volume":"39","author":"KA Jacobs","year":"2020","unstructured":"Jacobs, K. A. et al. Paracaspase MALT1 regulates glioma cell survival by controlling endo-lysosome homeostasis. EMBO J. 39, e102030 (2020).","journal-title":"EMBO J."},{"key":"76572_CR13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/onc.2015.146","volume":"35","author":"D Pan","year":"2016","unstructured":"Pan, D. et al. MALT1 is required for EGFR-induced NF-kappaB activation and contributes to EGFR-driven lung cancer progression. Oncogene 35, 919\u2013928 (2016).","journal-title":"Oncogene"},{"key":"76572_CR14","doi-asserted-by":"publisher","first-page":"7550","DOI":"10.1111\/jcmm.15383","volume":"24","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-kappaB activation. J. Cell Mol. Med. 24, 7550\u20137562 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"76572_CR15","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.3389\/fimmu.2018.01887","volume":"9","author":"JR McAuley","year":"2018","unstructured":"McAuley, J. R., Freeman, T. J., Ekambaram, P., Lucas, P. C. & McAllister-Lucas, L. M. CARMA3 is a critical mediator of G protein-coupled receptor and receptor tyrosine kinase-driven solid tumor pathogenesis. Front. Immunol. 9, 1887 (2018).","journal-title":"Front. Immunol."},{"key":"76572_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1158\/1541-7786.MCR-21-0208","volume":"20","author":"JL Lee","year":"2022","unstructured":"Lee, J. L. et al. MALT1 is a targetable driver of epithelial-to-mesenchymal transition in claudin-low, triple-negative breast cancer. Mol. Cancer Res. 20, 373\u2013386 (2022).","journal-title":"Mol. Cancer Res."},{"key":"76572_CR17","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/0008-5472.CAN-17-1089","volume":"78","author":"P Ekambaram","year":"2018","unstructured":"Ekambaram, P. et al. The CARMA3-Bcl10-MALT1 signalosome drives NFkappaB activation and promotes aggressiveness in angiotensin II receptor-positive breast cancer. Cancer Res. 78, 1225\u20131240 (2018).","journal-title":"Cancer Res."},{"key":"76572_CR18","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.15252\/embj.201488987","volume":"33","author":"M Jaworski","year":"2014","unstructured":"Jaworski, M. et al. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity. EMBO J. 33, 2765\u20132781 (2014).","journal-title":"EMBO J."},{"key":"76572_CR19","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.celrep.2014.10.044","volume":"9","author":"A Gewies","year":"2014","unstructured":"Gewies, A. et al. Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation. Cell Rep. 9, 1292\u20131305 (2014).","journal-title":"Cell Rep."},{"key":"76572_CR20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3389\/fimmu.2020.00745","volume":"11","author":"K Martin","year":"2020","unstructured":"Martin, K. et al. Pharmacological inhibition of MALT1 protease leads to a progressive IPEX-like pathology. Front. Immunol. 11, 745 (2020).","journal-title":"Front. Immunol."},{"key":"76572_CR21","doi-asserted-by":"publisher","first-page":"e0127083","DOI":"10.1371\/journal.pone.0127083","volume":"10","author":"JW Yu","year":"2015","unstructured":"Yu, J. W. et al. MALT1 protease activity is required for innate and adaptive immune responses. PLoS One 10, e0127083 (2015).","journal-title":"PLoS One"},{"key":"76572_CR22","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1002\/eji.201847597","volume":"48","author":"M Baens","year":"2018","unstructured":"Baens, M. et al. Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice. Eur. J. Immunol. 48, 1728\u20131738 (2018).","journal-title":"Eur. J. Immunol."},{"key":"76572_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1215-2","volume":"570","author":"M Di Pilato","year":"2019","unstructured":"Di Pilato, M. et al. Targeting the CBM complex causes T(reg) cells to prime tumours for immune checkpoint therapy. Nature 570, 112\u2013116 (2019).","journal-title":"Nature"},{"key":"76572_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10203-2","volume":"10","author":"M Rosenbaum","year":"2019","unstructured":"Rosenbaum, M. et al. Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells. Nat. Commun. 10, 2352 (2019).","journal-title":"Nat. Commun."},{"key":"76572_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113631","volume":"43","author":"C Maghe","year":"2024","unstructured":"Maghe, C. et al. The paracaspase MALT1 controls cholesterol homeostasis in glioblastoma stem-like cells through lysosome proteome shaping. Cell Rep. 43, 113631 (2024).","journal-title":"Cell Rep."},{"key":"76572_CR26","doi-asserted-by":"publisher","first-page":"9113","DOI":"10.1080\/21655979.2021.1977104","volume":"12","author":"X Zhong","year":"2021","unstructured":"Zhong, X. & Cai, Y. Long non-coding RNA (lncRNA) HOXD-AS2 promotes glioblastoma cell proliferation, migration and invasion by regulating the miR-3681-5p\/MALT1 signaling pathway. Bioengineered 12, 9113\u20139127 (2021).","journal-title":"Bioengineered"},{"key":"76572_CR27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ccr.2012.11.003","volume":"22","author":"L Fontan","year":"2012","unstructured":"Fontan, L. et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 22, 812\u2013824 (2012).","journal-title":"Cancer Cell"},{"key":"76572_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/imcb.1018","volume":"96","author":"M Bardet","year":"2018","unstructured":"Bardet, M. et al. The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibition. Immunol. Cell Biol. 96, 81\u201399 (2018).","journal-title":"Immunol. Cell Biol."},{"key":"76572_CR29","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1016\/j.bmc.2016.03.035","volume":"24","author":"BT Xin","year":"2016","unstructured":"Xin, B. T. et al. Development of new Malt1 inhibitors and probes. Bioorg. Med. Chem. 24, 3312\u20133329 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"76572_CR30","doi-asserted-by":"crossref","unstructured":"Mempel, T. R. & Krappmann, D. Combining precision oncology and immunotherapy by targeting the MALT1 protease. J. Immunother. Cancer 10, e005442 (2022).","DOI":"10.1136\/jitc-2022-005442"},{"key":"76572_CR31","doi-asserted-by":"publisher","first-page":"e1655360","DOI":"10.1080\/2162402X.2019.1655360","volume":"8","author":"I Kaffes","year":"2019","unstructured":"Kaffes, I. et al. Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncoimmunology 8, e1655360 (2019).","journal-title":"Oncoimmunology"},{"key":"76572_CR32","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.celrep.2017.10.030","volume":"21","author":"S Darmanis","year":"2017","unstructured":"Darmanis, S. et al. Single-cell RNA-seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep. 21, 1399\u20131410 (2017).","journal-title":"Cell Rep."},{"key":"76572_CR33","doi-asserted-by":"crossref","unstructured":"De Leo, A., Ugolini, A. & Veglia, F. Myeloid cells in glioblastoma microenvironment. Cells 10, 18 (2020).","DOI":"10.3390\/cells10010018"},{"key":"76572_CR34","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm, F. et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 181, 1643\u20131660 e1617 (2020).","journal-title":"Cell"},{"key":"76572_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41577-018-0087-2","volume":"19","author":"J Ruland","year":"2019","unstructured":"Ruland, J. & Hartjes, L. CARD-BCL-10-MALT1 signalling in protective and pathological immunity. Nat. Rev. Immunol. 19, 118\u2013134 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"76572_CR36","doi-asserted-by":"crossref","unstructured":"Kang, H. et al. A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma. J. Clin. Investig. 135, e164573 (2025).","DOI":"10.1172\/JCI164573"},{"key":"76572_CR37","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41589-018-0222-1","volume":"15","author":"J Quancard","year":"2019","unstructured":"Quancard, J. et al. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient. Nat. Chem. Biol. 15, 304\u2013313 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"76572_CR38","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1172\/JCI99436","volume":"128","author":"L Fontan","year":"2018","unstructured":"Fontan, L. et al. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. J. Clin. Investig. 128, 4397\u20134412 (2018).","journal-title":"J. Clin. Investig."},{"key":"76572_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1196\/annals.1443.024","volume":"1143","author":"J Ruland","year":"2008","unstructured":"Ruland, J. CARD9 signaling in the innate immune response. Ann. N. Y Acad. Sci. 1143, 35\u201344 (2008).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"76572_CR40","doi-asserted-by":"publisher","first-page":"11392","DOI":"10.1073\/pnas.1705748114","volume":"114","author":"ES Leshchiner","year":"2017","unstructured":"Leshchiner, E. S. et al. Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 114, 11392\u201311397 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76572_CR41","doi-asserted-by":"crossref","unstructured":"Cornice, J., et al. NF-kappaB: governing macrophages in cancer. Genes 15, 197 (2024).","DOI":"10.3390\/genes15020197"},{"key":"76572_CR42","doi-asserted-by":"crossref","unstructured":"Menck, K. et al. Isolation of human monocytes by double gradient centrifugation and their differentiation to macrophages in teflon-coated cell culture bags. J. Vis. Exp. 9, e51554 (2014).","DOI":"10.3791\/51554-v"},{"key":"76572_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-107","volume":"12","author":"T Oh","year":"2014","unstructured":"Oh, T. et al. Immunocompetent murine models for the study of glioblastoma immunotherapy. J. Transl. Med. 12, 107 (2014).","journal-title":"J. Transl. Med."},{"key":"76572_CR44","doi-asserted-by":"publisher","first-page":"927233","DOI":"10.3389\/fimmu.2022.927233","volume":"13","author":"G Wang","year":"2022","unstructured":"Wang, G., Wang, J., Niu, C., Zhao, Y. & Wu, P. Neutrophils: new critical regulators of glioma. Front. Immunol. 13, 927233 (2022).","journal-title":"Front. Immunol."},{"key":"76572_CR45","doi-asserted-by":"crossref","unstructured":"Koizumi, S. I. & Ishikawa, H. Transcriptional regulation of differentiation and functions of effector T regulatory cells. Cells 8, 939 (2019).","DOI":"10.3390\/cells8080939"},{"key":"76572_CR46","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s43018-021-00267-9","volume":"2","author":"K Zhai","year":"2021","unstructured":"Zhai, K. et al. Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells. Nat. Cancer 2, 1136\u20131151 (2021).","journal-title":"Nat. Cancer"},{"key":"76572_CR47","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s42003-025-08092-x","volume":"8","author":"L Garcia-Vicente","year":"2025","unstructured":"Garcia-Vicente, L. et al. Single-nucleus RNA sequencing reveals a preclinical model for the most common subtype of glioblastoma. Commun. Biol. 8, 671 (2025).","journal-title":"Commun. Biol."},{"key":"76572_CR48","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","volume":"10","author":"M Orecchioni","year":"2019","unstructured":"Orecchioni, M., Ghosheh, Y., Pramod, A. B. & Ley, K. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front Immunol. 10, 1084 (2019).","journal-title":"Front Immunol."},{"key":"76572_CR49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2022","unstructured":"Kohli, K., Pillarisetty, V. G. & Kim, T. S. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 29, 10\u201321 (2022).","journal-title":"Cancer Gene Ther."},{"key":"76572_CR50","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s10238-022-00888-z","volume":"23","author":"R Qin","year":"2023","unstructured":"Qin, R. et al. Role of chemokines in the crosstalk between tumor and tumor-associated macrophages. Clin. Exp. Med. 23, 1359\u20131373 (2023).","journal-title":"Clin. Exp. Med."},{"key":"76572_CR51","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ccr.2012.11.002","volume":"22","author":"D Nagel","year":"2012","unstructured":"Nagel, D. et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 22, 825\u2013837 (2012).","journal-title":"Cancer Cell"},{"key":"76572_CR52","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/neuonc\/noz015","volume":"21","author":"A Karachi","year":"2019","unstructured":"Karachi, A. et al. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol. 21, 730\u2013741 (2019).","journal-title":"Neuro Oncol."},{"key":"76572_CR53","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1093\/brain\/awaa343","volume":"143","author":"K Ayasoufi","year":"2020","unstructured":"Ayasoufi, K. et al. Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators. Brain 143, 3629\u20133652 (2020).","journal-title":"Brain"},{"key":"76572_CR54","doi-asserted-by":"crossref","unstructured":"Zamler, D. B., et al. Immune landscape of a genetically engineered murine model of glioma compared with human glioma. JCI Insight 7, e148990 (2022).","DOI":"10.1172\/jci.insight.148990"},{"key":"76572_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-124","volume":"11","author":"C Mc Guire","year":"2014","unstructured":"Mc Guire, C. et al. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis. J. Neuroinflammation 11, 124 (2014).","journal-title":"J. Neuroinflammation"},{"key":"76572_CR56","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/13543776.2025.2484371","volume":"35","author":"M Brvar","year":"2025","unstructured":"Brvar, M., O\u2019Neill, T. J., Plettenburg, O. & Krappmann, D. An updated patent review of MALT1 inhibitors (2021-present). Expert Opin. Ther. Pat. 35, 639\u2013656 (2025).","journal-title":"Expert Opin. Ther. Pat."},{"key":"76572_CR57","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/13543776.2021.1951703","volume":"31","author":"I Hamp","year":"2021","unstructured":"Hamp, I., O\u2019Neill, T. J., Plettenburg, O. & Krappmann, D. A patent review of MALT1 inhibitors (2013-present). Expert Opin. Ther. Pat. 31, 1079\u20131096 (2021).","journal-title":"Expert Opin. Ther. Pat."},{"key":"76572_CR58","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s11910-005-0047-7","volume":"5","author":"R Stupp","year":"2005","unstructured":"Stupp, R., van den Bent, M. J. & Hegi, M. E. Optimal role of temozolomide in the treatment of malignant gliomas. Curr. Neurol. Neurosci. Rep. 5, 198\u2013206 (2005).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"76572_CR59","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/neuonc\/noy072","volume":"20","author":"A Karachi","year":"2018","unstructured":"Karachi, A., Dastmalchi, F., Mitchell, D. A. & Rahman, M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 20, 1566\u20131572 (2018).","journal-title":"Neuro Oncol."},{"key":"76572_CR60","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1016\/j.bbagen.2017.07.007","volume":"1861","author":"JH Azambuja","year":"2017","unstructured":"Azambuja, J. H. et al. Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities. Biochim. Biophys. Acta Gen. Subj. 1861, 2652\u20132662 (2017).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"76572_CR61","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529 (2021).","journal-title":"Cell"},{"key":"76572_CR62","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research, N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061\u20131068 (2008).","DOI":"10.1038\/nature07385"},{"key":"76572_CR63","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550\u2013555 (2016).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76572-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:04:01Z","timestamp":1788865441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76572-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76572"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76572-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9577"}}